Literature DB >> 21342102

Imaging cellular receptors in breast cancers: an overview.

Thillai V Sekar1, Aradhana Dhanabalan, Ramasamy Paulmurugan.   

Abstract

Breast cancer, a leading cause of cancer death in women, is strongly correlated with the up- and down-regulation of hormone and growth factor receptors. Therefore, improving our understanding of such receptor status in different stages of breast cancer will help in the development of novel diagnostic and therapeutic solutions. In particular, molecular imaging technology in association with advanced molecular and cell biology techniques could reveal in detail dynamic molecular events in cells, allowing the study of crucial molecular pathological changes occurring in cancer and other diseases. Molecular imaging techniques such as PET, SPECT, MRI, and the combinatorial techniques have made tremendous strides in elucidating the role of cellular receptors, helping to monitor the course of breast cancer development and the therapeutic efficacy of novel drugs. Optical imaging of cellular receptors is emerging as a powerful tool given the advancement of fluorescent and bioluminescent proteins. Estrogen receptor, progesterone receptor, and HER2/neu have been adopted clinically to detect different types of breast cancer and to test novel treatment strategies; however, other cellular receptors may also be involved in breast cancer subtyping and could emerge as treatment prospects. This review will focus on the recent developments of imaging various cellular receptors pertaining to the growth and development of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21342102     DOI: 10.2174/138920111795164039

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  8 in total

1.  Failed PET Application Attempts in the Past, Can We Avoid Them in the Future?

Authors:  Gang Cheng; Thomas J Werner; Andrew Newberg; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2016-12       Impact factor: 3.488

2.  GPER-targeted, 99mTc-labeled, nonsteroidal ligands demonstrate selective tumor imaging and in vivo estrogen binding.

Authors:  Tapan K Nayak; Chinnasamy Ramesh; Helen J Hathaway; Jeffrey P Norenberg; Jeffrey B Arterburn; Eric R Prossnitz
Journal:  Mol Cancer Res       Date:  2014-07-16       Impact factor: 5.852

3.  Novel (64)Cu-Labeled CUDC-101 for in Vivo PET Imaging of Histone Deacetylases.

Authors:  Qingqing Meng; Feng Li; Sheng Jiang; Zheng Li
Journal:  ACS Med Chem Lett       Date:  2013-07-25       Impact factor: 4.345

4.  Quantification of receptor-ligand binding with [¹⁸F]fluciclatide in metastatic breast cancer patients.

Authors:  Giampaolo Tomasi; Laura Kenny; Francesco Mauri; Federico Turkheimer; Eric O Aboagye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-03       Impact factor: 9.236

5.  Distribution of breast cancer subtypes among Jordanian women and correlation with histopathological grade: molecular subclassification study.

Authors:  Maha Shomaf; Jamal Masad; Saleh Najjar; Dana Faydi
Journal:  JRSM Short Rep       Date:  2013-09-13

6.  Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.

Authors:  Michele Balma; Virginia Liberini; Manuela Racca; Riccardo Laudicella; Matteo Bauckneht; Ambra Buschiazzo; Daniele Giovanni Nicolotti; Simona Peano; Andrea Bianchi; Giovanni Albano; Natale Quartuccio; Ronan Abgral; Silvia Daniela Morbelli; Calogero D'Alessandria; Enzo Terreno; Martin William Huellner; Alberto Papaleo; Désirée Deandreis
Journal:  Front Med (Lausanne)       Date:  2022-04-12

7.  Molecular imaging probes for diagnosis and therapy evaluation of breast cancer.

Authors:  Qingqing Meng; Zheng Li
Journal:  Int J Biomed Imaging       Date:  2013-02-26

Review 8.  The role of general nuclear medicine in breast cancer.

Authors:  Lacey R Greene; Deborah Wilkinson
Journal:  J Med Radiat Sci       Date:  2015-02-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.